HighVista Strategies’s BioMarin Pharmaceuticals BMRN Stock Holding History

HighVista Strategies’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-7,993	Closed	-$693K	–	142
2023 Q2	$693K	Sell	7,993 -1,708	-18%	-$161K	0.32%	90
2023 Q1	$943K	Hold	9,701	–	–	0.77%	38
2022 Q4	$1M	Sell	9,701 -120	-1%	-$11.3K	0.6%	43
2022 Q3	$833K	Buy	9,821 +1,225	+14%	+$109K	0.48%	51
2022 Q2	$712K	Buy	8,596 +3,003	+54%	+$239K	0.43%	55
2022 Q1	$431K	Buy	+5,593	New	+$468K	0.27%	79
2020 Q3	–	Sell	-3,384	Closed	-$417K	–	119
2020 Q2	$417K	Buy	+3,384	New	+$336K	0.35%	53

Other funds holding BMRN

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

HighVista Strategies's BMRN Position: Q3 2023 in Review

HighVista Strategies sold out of BioMarin Pharmaceuticals (BMRN) in Q3 2023, closing a stake of 7,993 shares — an estimated $693K sold.

HighVista Strategies first reported a position in BMRN in Q2 2020 and held it in 7 quarters. The position peaked at $1M in Q4 2022. 519 funds tracked by Wall St. Rank hold BMRN as of Q3 2023.

HighVista Strategies reported no remaining BioMarin Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
HighVista Strategies sold 7,993 BioMarin Pharmaceuticals shares in Q3 2023, an estimated $693K.
HighVista Strategies first reported a position in BioMarin Pharmaceuticals in Q2 2020 and held it in 7 quarters.
HighVista Strategies's BioMarin Pharmaceuticals position peaked at $1M in Q4 2022.
519 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q3 2023.

Based on HighVista Strategies's 13F filing for Q3 2023, filed 14 Nov 2023.